Update shared on17 Aug 2025
Fair value Decreased 5.23%The slight decrease in consensus revenue growth expectations and a lower future P/E multiple have led analysts to reduce their fair value estimate for Pacira BioSciences from $30.60 to $29.00.
What's in the News
- Pacira completed a $50.04 million buyback, repurchasing 1,955,589 shares (4.23%) under its May 2025 authorization and previously completed a $25 million buyback (837,240 shares, 1.8%) under its May 2024 authorization.
- Earnings guidance for FY2025 narrowed to $730–750 million in total revenue, from a prior range of $725–765 million.
- Formed a strategic collaboration with Johnson & Johnson MedTech to co-promote ZILRETTA®, expanding its reach beyond orthopedics into specialties such as sports medicine, pain management, and rheumatology.
- Announced positive, long-term Phase 1 results for PCRX-201, a gene therapy candidate for osteoarthritis of the knee, with sustained pain and function improvement over three years and regulatory designations (RMAT and ATMP) in the U.S. and Europe; Phase 2 dosing underway.
- Pacira was dropped from the Russell 2000 Defensive, Growth-Defensive, and Value-Defensive indices.
Valuation Changes
Summary of Valuation Changes for Pacira BioSciences
- The Consensus Analyst Price Target has fallen from $30.60 to $29.00.
- The Future P/E for Pacira BioSciences has fallen from 13.63x to 12.92x.
- The Consensus Revenue Growth forecasts for Pacira BioSciences has fallen slightly from 9.2% per annum to 8.8% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.